Vilazodone is the first member of the serotonin partial agonist-reuptake inhibitor (SPARI) class of medications, which combines serotonin reuptake inhibition with 5-HT1A partial agonist action, approved by the Food and Drug Administration (FDA) for the treatment of MDD in adults [6]. Here, HTR1A is linked to major depressive disorder.